REBECCA GLEASON: Open Payments
NPI 1972936938 · FLINT, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,353 in 67 payments from 11 companies in 2025. Trend: 2023 $594 · 2024 $621 · 2025 $1,353
Food & beverage: $1,353
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 18 | $425 |
| Otsuka America Pharmaceutical, Inc. | 21 | $352 |
| E.R. Squibb & Sons, L.L.C. | 8 | $159 |
| Teva Pharmaceuticals USA, Inc. | 4 | $93 |
| Neurocrine BioSciences, Inc. | 5 | $88 |
| ABBVIE INC. | 4 | $68 |
| Vanda Pharmaceuticals Inc. | 2 | $67 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $47 |
| Tris Pharma Inc | 1 | $22 |
| Janssen Biotech, Inc. | 1 | $20 |
Products named: ARISTADA, COBENFY, REXULTI, ABILIFY ASIMTUFII, ABILIFY MAINTENA, INGREZZA, VRAYLAR, FANAPT.
Industry payments across MI — which companies pay providers there.
